Nitric oxide and almitrine: The definitive answer for hypoxemia

Current Opinion in Anaesthesiology

Volumn 12, Issue 1, 1999, Pages 37-42

  Payen, Didier M ^a   Muret, Jane ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALMITRINE DIMESILATE; NITRIC OXIDE;

HUMAN; HYPOXIC LUNG VASOCONSTRICTION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD FLOW; LUNG INJURY; LUNG VENTILATION PERFUSION RATIO; METABOLIC ACIDOSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0033046090     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199902000-00007     Document Type: Review

References (47)

1. West J, Wagner P. Ventilation-perfusion relationship. In: The lung: scientific foundations. Crystal R, West J (editors). New York: Raven Press; 1991. pp. 1289-1306.
2. Marshall B, Marshall C, Frasch F, Hanson C. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. Intens Care Med 1994; 20:291-297.
3. Voelkel N, Mechanisms of hypoxic pulmonary vasoconstriction. Am Rev Raspir Dis 1986; 133:1186-1195.
4. Payen D, Carli P, Brun-Buisson C, Huet Y, Teisseire B, Lemaire F. Lower body positive pressure versus dopamine during PEEP ventilation. J Appl Physiol 1985; 58;77-82.
5. Marshall C, Marshall B. Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction. J Appl Physiol 1983; 55:711-716.
6. 2 on pulmonary vascular resistance. J Appl Physiol 1991; 70:405-415.
7. Marshall B, Hanson C, Frasch F, Marshall C. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. Intens Care Med 1994; 20:379-389.
8. Domino K, Wetstein L, Glasser S, Lindgren L, Marshall C, Harken A. Influence of mixed venous oxygen tension on blood flow to atelectatic lung. Anesthesiology 1983; 59;428-434.
9. Persson MG, Gustafsson LE, Wiklund NP, Moncada S, Hedqvist P. Endogenous nitric oxide as a probable modulator of pulmonary circulation and hypoxic pressor response in vivo. Acta Physiol Scand 1990; 140:449-457.
10. Sprague R, Thiemermann C, Vane J. Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits. Proc Natl Acad Sci USA 1992; 69:8711-8715.
11. Light R. Effect of sodium nitroprusside and diethylcarbamazine on hypoxic pulmonary vasoconstriction and regional distribution of pulmonary blood flow in experimental pneumonia. Am J Respir Crit Care Med 1996; 153:325-330.
12. Frostell C, Fratacci M, Wain J, Jones R, Zapol W. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83:2038-2047.
13. Fratacci M, Frostell C, Chen T, Wain JJ, Robinson D, Zapol W. Inhaled nitric oxide: a selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75:990-999.
14. Westfelt UN, Lundin S, Stenqvist O. Uptake of inhaled nitric oxide in acute lung injury. Acta Anaesthesiol Scand 1997; 41:818-823. A different fraction of inhaled nitric oxide was tested in 40 ALI patients with 95% of alveolar nitric oxide being taken up.
15. 2O production and cytokine release in ARDS patients.
16. Kermarrec N, Zunic P, Beloucif S, Benessiano J, Dronet L, Payen D. Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxinic lung injury. Role of cGMP. Am J Rasp Crit Care Med 1998: 158:833-839. Using a rat model, the authors have shown for the first time the increase in cGMP content in platelets and aortic vessel walls after nitric oxide inhalation This study confirms the presence of nitric oxide stores acting at distance from the lung.
17. Rossaint R, Falke K, Lopez F, Slama K, Pison U, Zapol W. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399-405.
18. Matthay MA, Pittet JF, Jayr G. Just say NO to inhaled nitric oxide for the acute respiratory distress syndrome [editorial and comment]. Crit Care Med 1998; 26:1-2.
19. 2 deterioration when inhaled nitric oxide reaches low VA/Q zones.
20. Graham L, Vasil A, Vasil M, Voelkel N, Stenmark K. Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Rasp Dis 1990; 142:221-229.
21. Spaden H, Vincken W. Pulmonary arterial hypertension in sepsis and the adult respiratory distress syndrome. Acta Clin Belg 1987; 47:30-40.
22. Laubie M, Diot F. A pharmacological study of the respiratory stimulant action of S 2620. J Pharmacol 1972; 3:363-374.
23. Payen D, Gatecel C, Kermarrec N, Beloucif S. Almitrine and inhaled nitric oxide in acute respiratory failure. In: Nitric oxide and the lung. Zapol W, Bloch K (editors). New York: Marcel Dekker; 1997. pp. 313-332.
24. Laubie M, Schmitt H. Long-lasting hyperventilation induced by almitrine: evidence for a specific effect on carotid and thoracic chemoreceptors. Eur J Pharmacol 1980; 61:125-136.
25. Gherardi R, Louam F, Benvenuti C, Perrier M, Lejonc J, Schaeffer A, et al. Peripheral neuropathy in patients treated with almitrine bismesylate. Lancet 1985; 2:1247-1250.
26. Voisin C, Howard P, Ansquer JC. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD - Vectarion International Multicentre Study Group. Bull Eur Physiopathol Respir 1987; 23:169S-182S.
27. Reyes A, Lopez-Messa JB, Alonso P. Almitrine in acute respiratory failure. Effects on pulmonary gas exchange and circulation. Chest 1987; 91:388-393.
28. Sicsic JC, Jugan E, Moine P, Edouard A, Samii K. Reversible hepatic cytolysis during almitrine bismesylate treatment for posttraumatic ARDS [letter]. Intens Care Med 1996; 22; 173-174.
29. B'Chir A, Mebazaa A, Losser M, Romieu M, Payen D. Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury. Anesthesiology 1998; 89:823-830. In 25 ALI patients treated with almitrine, eight had a lactic acidosis associated with a modification of hepatic function tests. All abnormalities were rapidly reversible when almitrine was stopped
30. Rigoulet M, Ouhabi R, Leverve X, Putod-Paramelle F, Guerin B. Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta 1989; 975:325-329.
31. 2 sensor in rat pulmonary vasculature. Circ Res 1993; 73:1100-1112.
32. Melot C, Naieje R, Rotschild T, Mertens P, Mols P, Hallemans R. Improvement in ventilation-perfusion matching by almitrine in COPD. Chest 1983; 83:528-533.
33. Romaldini H, Rodriguez-Roisin R, Wagner P, West J. Enhancement of hypoxic pulmonary vasoconstriction by almitrine in the dog. Am Rev Resp Dis 1983; 128:288-293.
34. Rayes A, Roca J, Rodriguez-Roisin R, Torres A, Ussetti P, Wagner PD. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137:1062-1067.
35. Bee D, Gill G, Emery C, Salmon G, Evans T, Barer G. Action of almitrine on the pulmonary vasculature in ferrets and rats. Bull Eur Physiopath Resp 1983; 19:539-545.
36. Falus F, Harget J, Hampl V. Almitrine in low dose potentiates vasoconstrictor responses of isolated rat lungs to moderate hypoxia. Eur Respir J 1991; 4:688-693.
37. Chen L, Miller FL, Clarke WR, Clergue FX, Marshall C, Marshall BE. Low-dose almitrine bismesylate enhances hypoxic pulmonary vasoconstriction in closed-chest dogs. Anesth Analg 1990; 71:475-483.
38. Chen L, Miller FL, Malmkvist G, Clergue FX, Marshall C, Marshall BE. High-dose almitrine bismesylate inhibits hypoxic pulmonary vasoconstriction in closed-chest dogs. Anesthesiology 1987; 67:534-542.
39. Gottschall EB, Fernyak S, Wuertemberger G, Voelkel NF. Almitrine mimics hypoxic vasoconstriction in isolated rat lungs. Am J Physiol 1992; 263:H383-H391.
40. Payen DM, Gatecel C, Plaisance P. Almitrine effect on nitric oxide inhalation in adult respiratory distress syndrome [letter]. Lancet 1993; 341:1664.
41. Wysocki M, Delclaux C, Roupie E, Langeron O, Liu N, Herman B, et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intens Care Med 1994; 20:254-259.
42. Lu Q, Mourgeon E, Law-Koune JD, Roche S, Vezinet C, Abdennour L, et al. Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology 1995; 83:929-943.
43. 2O.
44. 2, without deleterious effects.
45. 2 in 36 severe ARDS patients. The responders to this strategy had a much better outcome than non responders. The results suggest to test a strategy of care involving more than one interventional method to evaluate the potential reversibility of the disease.
46. Payen D. Is nitric oxide inhalation a 'cosmetic' therapy in acute respiratory distress syndrome? Am J Resp Crit Care Med 1998; 157:1361-1362.
47. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15-23. This is the first reported phase II clinical trial of inhaled nitric oxide on 177 ARDS patients This randomized placebo-controlled study demonstrated the safety of nitric oxide inhalation and defined the best nitric oxide fraction to use, but failed to suggest any positive effect on outcome.